

Supplementary Table 1 ORAL Start: baseline patient demographics and disease characteristics according to CDAI response at Month 6

	Month 6 CDAI remission (≤ 2.8)			Month 6 CDAI LDA without remission (> 2.8 to ≤ 10)			Month 6 CDAI MDA/HDA (> 10)		
	Tofacitinib 5 mg	Tofacitinib 10 mg	MTX	Tofacitinib 5 mg	Tofacitinib 10 mg	MTX	Tofacitinib 5 mg	Tofacitinib 10 mg	MTX
Baseline parameter	(N = 42)	(N = 77)	(N = 14)	(N = 116)	(N = 143)	(N = 40)	(N = 178)	(N = 143)	(N = 102)
Mean age ^a	50.2	45.1	49.0	50.6	50.6	49.0	50.2	50.8	48.6
Female, %	71.4	75.3	92.9	75.0	80.4	65.0	79.8	86.7	80.4
Mean disease duration ^a	2.5	2.1	1.6	2.8	3.2	3.0	3.3	4.1	2.8
Mean DAS28(ESR)	5.9	6.3	6.2	6.5	6.4	6.1	6.8	6.8	6.8
Mean mTSS	6.7	7.2	15.9	17.1	18.8	10.8	22.9	23.9	18.5

Mean CDAI	32.4	34.9	35.9	38.0	36.4	33.6	41.2	42.2	40.9
Mean DAS28CRP	5.2	5.5	5.3	5.7	5.7	5.5	6.0	6.0	6.0
Mean HAQ-DI	1.2	1.4	1.4	1.5	1.5	1.3	1.6	1.6	1.6

^aYears

CDAI Clinical Disease Activity Index, *CRP* C-reactive protein, *DAS28* Disease Activity Score defined using 28 joint counts, *ESR* erythrocyte sedimentation rate, *HAQ-DI* Health Assessment Questionnaire-Disability Index, *LDA* low disease activity, *MDA/HDA* moderate/high disease activity, *mTSS* van der Heijde modified Total Sharp Score, *MTX* methotrexate

Supplementary Table 2 ORAL Scan: baseline patient demographics and disease characteristics according to CDAI response at Month 6

	Month 6 CDAI remission (≤ 2.8)		Month 6 CDAI LDA without remission (>2.8 to ≤ 10)		Month 6 CDAI MDA/HDA (>10)	
	Tofacitinib	Tofacitinib	Tofacitinib	Tofacitinib	Tofacitinib	Tofacitinib
	5 mg (N = 28)	10 mg (N = 44)	5 mg (N = 97)	10 mg (N = 101)	5 mg (N = 156)	10 mg (N = 138)
Baseline parameter						
Mean age ^a	54.1	51.3	53.9	49.8	52.5	52.8
Female, %	71.4	86.4	82.5	86.1	85.3	86.2
Mean disease duration ^a	6.2	9.0	9.6	8.0	8.1	9.6
Mean DAS28ESR	6.1	5.8	6.1	6.1	6.5	6.5
Mean mTSS	20.1	36.7	29.3	31.1	38.6	45.7

Mean CDAI	33.2	29.1	32.1	32.1	38.3	38.7
Mean DAS28CRP	5.3	5.0	5.2	5.3	5.6	5.7
Mean HAQ-DI	1.1	1.4	1.3	1.2	1.5	1.6

^aYears

CDAI Clinical Disease Activity Index, *CRP* C-reactive protein, *DAS28* Disease Activity Score defined using 28 joint counts, *ESR* erythrocyte sedimentation rate, *HAQ-DI* Health Assessment Questionnaire-Disability Index, *LDA* low disease activity, *MDA/HDA* moderate/high disease activity, *mTSS* van der Heijde modified Total Sharp Score